AbCellera Biologics Inc. (NASDAQ: ABCL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
12.63
-0.10-0.79%
News
Down 0.8% — AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 (businesswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.54 | Insider Own | - | Shs Outstand | 305.38M | Perf Week | 15.98% |
| Market Cap | 4.09B | Forward P/E | - | EPS next Y | -0.72 | Insider Trans | 0.08% | Shs Float | 205.09M | Perf Month | 5.16% |
| Enterprise Value | 3.45B | PEG | - | EPS next Q | -0.18 | Inst Own | - | Short Float | 16.95% | Perf Quarter | 128.39% |
| Income | -164.00M | P/S | 58.44 | EPS this Y | -21.43% | Inst Trans | - | Short Ratio | 4.44 | Perf Half Y | 257.79% |
| Sales | 66.00M | P/B | 4.30 | EPS next Y | -9.30% | ROA | -12.59% | Short Interest | 34.75M | Perf YTD | 269.30% |
| Book/sh | 2.93 | P/C | 7.14 | EPS next 5Y | - | ROE | -17.49% | 52W High | 13.18 -4.17% | Perf Year | 176.37% |
| Cash/sh | 1.77 | P/FCF | - | EPS past 3/5Y | - | ROIC | -14.95% | 52W Low | 2.75 359.27% | Perf 3Y | 140.57% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -46.32% -20.28% | Gross Margin | 74.95% | Volatility | 6.54% 5.90% | Perf 5Y | -33.49% |
| Dividend TTM | - | EV/Sales | 52.23 | EPS Y/Y TTM | 1.82% | Oper. Margin | -340.25% | ATR (14) | 0.75 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.63 | Sales Y/Y TTM | 127.59% | Profit Margin | -248.83% | RSI (14) | 66.62 | Recom | 2.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.77 | EPS Q/Q | -50.00% | SMA20 | 9.36% | Beta | 1.40 | Target Price | 15.33 |
| Payout | 0.00% | Debt/Eq | 0.14 | Sales Q/Q | -76.47% | SMA50 | 38.72% | Rel Volume | 0.73 | Prev Close | 12.73 |
| Employees | 562 | LT Debt/Eq | 0.14 | Earnings | Nov 05 | SMA200 | 129.95% | Avg Volume | 7.46M | Price | 12.63 |
| IPO Date | Dec 11, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -29.49% -48.39% | Net Debt/EBITDA | -0.10 | Volume | 5,419,358 | Change | -0.79% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Reiterated | Truist Securities | Buy | $29 → $30 |
| Aug-06-26 | Reiterated | Stifel Nicolaus | $8.00 → $9.00 | |
| Jul-07-26 | Upgrade | Benchmark | Hold → Buy | |
| May-12-26 | Reiterated | Stifel Nicolaus | $7.00 → $8.00 | |
| May-05-26 | Initiated | Cantor Fitzgerald | Overweight | $7.00 |
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform | |
| Nov-05-24 | Reiterated | BMO Capital | Outperform | $5.00 |
| Aug-23-24 | Reiterated | KeyBanc | Overweight | $7.00 → $5.00 |
| Aug-20-24 | Downgrade | Benchmark | Buy → Hold | |
| May-08-24 | Reiterated | Keybanc | Overweight | $7.00 |
Latest News· Times ET
Sep-16-26
Sep-16-2612:05PM
Sep-02-26
Sep-02-2612:05PM
12:36AM
Aug-25-26
Aug-16-26
Aug-12-26
Aug-12-2608:05PM
09:54AM
Aug-11-26
Aug-11-2612:01PM
Aug-10-26
Aug-10-2609:21PM
12:38PM
10:12AM
07:05AM
05:04AM
Company
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 66 | 75 | 29 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 17 | 29 | 0 | — | — | — | — | — | — | |
| Gross Profit | 50 | 46 | 29 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 65 | 77 | 85 | — | — | — | — | — | — | |
| Research and Development | 198 | 187 | 167 | — | — | — | — | — | — | |
| Other Operating Expense | 12 | -1 | 92 | — | — | — | — | — | — | |
| Operating Income | -226 | -217 | -315 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 40 | 114 | — | — | — | — | — | — | |
| Net Income Before Taxes | -197 | -178 | -200 | — | — | — | — | — | — | |
| Income Taxes | -33 | -31 | -38 | — | — | — | — | — | — | |
| Consolidated Net Income | -164 | -146 | -163 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -164 | -146 | -163 | — | — | — | — | — | — | |
| Net Income | -164 | -146 | -163 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.54 | -0.49 | -0.55 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.54 | -0.49 | -0.55 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.54 | -0.49 | -0.55 | — | — | — | — | — | — | |
| EBITDA | -161 | -149 | -204 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 58.56 | 13.63 | 29.70 | — | — | — | — | — | — | |
| Gross Margin | 75.76 | 61.33 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -342.42 | -289.33 | -1,086.21 | — | — | — | — | — | — | |
| Net Margin | -248.48 | -194.67 | -562.07 | — | — | — | — | — | — | |
| Shares Outstanding | 306 | 299 | 294 | — | — | — | — | — | — | |
| Market Capitalization | 3,865 | 1,023 | 861 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director | Aug 24 '26 | Buy | 10.64 | 53,613 | 570,442 | 1,373,397 | Aug 24 |
| Montalbano John S. | Director | Aug 18 '26 | Buy | 11.03 | 10,000 | 110,300 | 251,000 | Aug 18 |
| Booth Andrew | Chief Financial Officer | Aug 14 '26 | Buy | 10.32 | 37,200 | 383,904 | 482,800 | Aug 14 |
| Hayden Michael R | Director | Aug 12 '26 | Buy | 10.37 | 46,387 | 481,033 | 1,319,784 | Aug 14 |
| Montalbano John S. | Director | May 14 '26 | Buy | 4.77 | 20,000 | 95,400 | 241,000 | May 18 |
| Thermopylae Holdings Ltd. | 10% Owner | Feb 27 '26 | Buy | 3.44 | 38,000 | 130,720 | 56,134,097 | Mar 02 |
| Booth Andrew | Chief Financial Officer | Feb 27 '26 | Buy | 3.42 | 42,600 | 145,692 | 195,600 | Feb 27 |
| Thermopylae Holdings Ltd. | 10% Owner | Feb 26 '26 | Buy | 3.27 | 177,457 | 580,284 | 56,096,097 | Feb 27 |
| Montalbano John S. | Director | Nov 26 '25 | Buy | 3.57 | 50,000 | 178,460 | 221,000 | Nov 26 |
| Thermopylae Holdings Ltd. | 10% Owner | Mar 11 '25 | Buy | 2.16 | 343,631 | 742,243 | 56,143,640 | Mar 11 |
| Montalbano John S. | Director | Mar 10 '25 | Buy | 2.30 | 25,000 | 57,500 | 171,000 | Mar 10 |
| Montalbano John S. | Director | Mar 06 '25 | Buy | 2.34 | 60,000 | 140,568 | 146,000 | Mar 07 |
| Hansen Carl L. G. | Chief Executive Officer | Nov 25 '24 | Option Exercise | 2.70 | 56,125 | 151,538 | 898,000 | Nov 26 |
| Hansen Carl L. G. | Chief Executive Officer | Sep 20 '24 | Option Exercise | 2.70 | 56,125 | 151,538 | 841,875 | Sep 24 |
| Thermopylae Holdings Ltd. | 10% Owner | Aug 29 '24 | Buy | 2.61 | 283,516 | 739,977 | 56,086,009 | Aug 29 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.